Evommune, Inc.
EVMN
$20.49
$0.301.49%
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -100.00% | |||
| SG&A Expenses | -28.76% | 152.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.39% | 27.38% | |||
| Operating Income | 19.39% | -122.96% | |||
| Income Before Tax | 23.34% | -126.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.34% | -126.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.34% | -126.64% | |||
| EBIT | 19.39% | -122.96% | |||
| EBITDA | 19.68% | -125.78% | |||
| EPS Basic | 54.98% | 82.29% | |||
| Normalized Basic EPS | 54.97% | 82.29% | |||
| EPS Diluted | 54.98% | 82.29% | |||
| Normalized Diluted EPS | 54.97% | 82.29% | |||
| Average Basic Shares Outstanding | 70.26% | 1,179.99% | |||
| Average Diluted Shares Outstanding | 70.26% | 1,179.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||